Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | CTSG | P08311 | 1/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | GCG | P01275 | 8/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1765614 | 0.85 | PRSS1 (0.46) | SMN1; SMN2MAPTPRSS1CTSGCTRB1 | |
| SCHEMBL2655859 | 0.83 | SMN1; SMN2 (0.44) | SMN1; SMN2MAPTPRSS1CTSGCTRB1 | |
| SCHEMBL1765766 | 0.78 | GCG (0.58) | SMN1; SMN2MAPTGCGALDH1A1HPGD | |
| SCHEMBL1765572 | 0.78 | SMN1; SMN2 (0.46) | SMN1; SMN2MAPTPRSS1CTSGCTRB1 | |
| SCHEMBL1765575 | 0.78 | SMN1; SMN2 (0.46) | SMN1; SMN2MAPTPRSS1CTSGCTRB1 | |
| SCHEMBL11901025 | 0.78 | PRSS1 (0.49) | SMN1; SMN2MAPTPRSS1CTSGCTRB1 | |
| SCHEMBL19922232 | 0.77 | MAPT (0.47) | MAPTALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL1765307 | 0.77 | GCGR (0.46) | SMN1; SMN2MAPTGCG | |
| SCHEMBL1765462 | 0.76 | GCGR (0.56) | SMN1; SMN2MAPTALDH1A1HPGDNPC1 | |
| SCHEMBL1765786 | 0.76 | GCG (0.58) | SMN1; SMN2MAPTGCGALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200377462-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-03 | — | — | US | disclosed |
| US-10774048-B2 | Indazole derivatives useful as glucagon receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-15 | — | — | US | disclosed |
| EP-3510026-B1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-12 | — | — | EP | disclosed |
| EP-3510028-B1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-05 | — | — | EP | disclosed |
| US-20190218186-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-18 | — | — | US | disclosed |
| EP-3510028-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | Janssen Pharmaceutica NV (BE) | 2019-07-17 | — | — | EP | disclosed |
| EP-3510026-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | Janssen Pharmaceutica NV (BE) | 2019-07-17 | — | — | EP | disclosed |
| US-10000473-B2 | Indazole derivatives useful as glucagon receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-19 | — | — | US | disclosed |
| WO-2018048762-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018048763-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-15 | — | — | WO | disclosed |
| US-20180065934-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-08 | — | — | US | disclosed |
| US-20180065955-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774048-B2 | Indazole derivatives useful as glucagon receptor antagonists | GPR119, GLP1R, GIPR | SMN1; SMN2 4836/4885MAPT 3988/4885PRSS1 3383/4885 |
| US-20180065934-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | GPR119, GLP1R, GIPR | SMN1; SMN2 4836/4885MAPT 3988/4885PRSS1 3383/4885 |
| US-20200377462-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | GPR119, GLP1R, GIPR | SMN1; SMN2 4836/4885MAPT 3988/4885PRSS1 3383/4885 |
| US-20180065955-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | GPR119, GLP1R, GIPR | SMN1; SMN2 4836/4885MAPT 3988/4885PRSS1 3383/4885 |
| US-20190218186-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | GPR119, GLP1R, GIPR | SMN1; SMN2 4836/4885MAPT 3988/4885PRSS1 3383/4885 |
| US-10000473-B2 | Indazole derivatives useful as glucagon receptor antagonists | GPR119, GLP1R, GIPR | SMN1; SMN2 4836/4885MAPT 3988/4885PRSS1 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.